Lactoferrin Supplementation to Prevent Late-Onset Sepsis in Preterm Infants: A Meta-Analysis

Abstract

Objective This study aimed to systematically review and meta-analyze the role of lactoferrin supplementation to prevent late-onset sepsis (LOS) in preterm infants.

Study Design Database search include PubMed, Web of Science, and Cochrane central for randomized clinical trial (RCTs). The Cochrane Grading of Recommendations Assessment, Development, and Evaluation methodology was used for summarizing the results.

Results Ten RCTs involving 3,679 infants were included. Lactoferrin supplementation with or without probiotics decreased all LOS (relative risk [RR]: 0.56; 95% confidence interval [CI]: 0.36–0.86; I ² = 58%; 10 studies; 3,470 subjects; level of evidence [LOE]: low) significantly. Similarly, lactoferrin supplementation without probiotics decreased all LOS (RR: 0.43; 95% CI: 0.29–0.62; I ² = 0%; 8 studies; 1,209 subjects; LOE: moderate) significantly. Lactoferrin supplementation did not significantly reduce necrotizing enterocolitis (RR: 0.62; 95% CI: 0.29–1.33; I ² = 43%; 6 studies; 3,079 subjects; LOE: low), all-cause mortality (RR: 0.74; 95% CI: 0.36–1.53; I ² = 53%; 8 studies; 3,395 subjects; LOE: very low), bronchopulmonary dysplasia (RR: 1; 95% CI: 0.90–1.13; I ² = 0%; 4 studies; 2,570 subjects; LOE: moderate), and threshold retinopathy of prematurity eligible for surgical treatment (RR: 0.61; 95% CI: 0.25–1.51; I ² = 74%; 2 studies; 2,481 subjects; LOE: very low).

Conclusion Low to moderate quality evidence suggests that lactoferrin supplementation reduces LOS in preterm infants. Further research is needed to improve the certainty in the evidence.

Keywords

lactoferrin - preterm - low birth weight - sepsis - fungal infection

• References

• 1 Dong Y, Speer CP. Late-onset neonatal sepsis: recent developments. Arch Dis Child Fetal Neonatal Ed 2015; 100 (03) F257-F263
• 2 Bassler D, Stoll BJ, Schmidt B. et al; Trial of Indomethacin Prophylaxis in Preterms Investigators. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics 2009; 123 (01) 313-318
• 3 Embleton ND, Berrington JE, McGuire W, Stewart CJ, Cummings SP. Lactoferrin: antimicrobial activity and therapeutic potential. Semin Fetal Neonatal Med 2013; 18 (03) 143-149
• 4 Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2017; 6: CD007137
• 5 Griffiths J, Jenkins P, Vargova M. et al; ELFIN trial investigators group. Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial. Lancet 2019; 393 (10170): 423-433
• 6 Welch V, Petticrew M, Petkovic J. et al; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration. Int J Equity Health 2015; 14 (01) 92
• 7 Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33 (01) 179-201
• 8 Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163 (07) 1723-1729
• 9 Higgins JPT, Green S. eds. Cochrane Handbook for Systematic Reviews of Interventions. West Sussex, United Kingdom: Wiley; 2011
• 10 Schunemann H, Brożek J, Guyatt G, Oxman A. eds. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. West Sussex, United Kingdom: Cochrane; 2015
• 11 Akin IM, Atasay B, Dogu F. et al. Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. Am J Perinatol 2014; 31 (12) 1111-1120
• 12 Manzoni P, Meyer M, Stolfi I. et al. Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial. Early Hum Dev 2014; 90 (Suppl. 01) S60-S65
• 13 Dai JZ, Xie C. The effect of lactoferrin supplementation combining lactobacillus rhamnosus for prevention of late-onset sepsis in premature neonates. China Pract Med 2015; 10: 98-100
• 14 Kaur G, Gathwala G. Efficacy of bovine lactoferrin supplementation in preventing late-onset sepsis in low birth weight neonates: a randomized placebo-controlled clinical trial. J Trop Pediatr 2015; 61 (05) 370-376
• 15 Ochoa TJ, Zegarra J, Cam L. et al; NEOLACTO Research Group. Randomized controlled trial of lactoferrin for prevention of sepsis in Peruvian neonates less than 2500 g. Pediatr Infect Dis J 2015; 34 (06) 571-576
• 16 Barrington KJ, Assaad MA, Janvier A. The Lacuna trial: a double-blind randomized controlled pilot trial of lactoferrin supplementation in the very preterm infant. J Perinatol 2016; 36 (08) 666-669
• 17 Liu YH, Guan HS, Liang GJ. et al. The effect of lactoferrin on low birth weight neonates during hospitalization. MCH Care China 2016; 31: 4464-4465
• 18 Sherman MP, Adamkin DH, Niklas V. et al. Randomized controlled trial of talactoferrin oral solution in preterm infants. J Pediatr 2016; 175: 68-73.e3
• 19 Tang JP, Sun HQ, Zheng YH. et al. Randomized control trial of lactoferrin for prevention of late onset sepsis in premature infants. MCH Care China 2017; 32: 1223-1225
• 20 Manzoni P, Rinaldi M, Cattani S. et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009; 302 (13) 1421-1428
• 21 Manzoni P, Stolfi I, Messner H. et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections–the Italian Society of Neonatology. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 2012; 129 (01) 116-123
• 22 He Y, Cao L, Yu J. Prophylactic lactoferrin for preventing late-onset sepsis and necrotizing enterocolitis in preterm infants: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2018; 97 (35) e11976